We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prescriptions for GLP-1 receptor agonists and SGLT2 ...

Henagliflozin, a diabetes treatment approved in China, may do more than just control blood sugar—it may actually slow ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

A new Northwestern Medicine study has shed light on how a class of diabetes drugs may protect the kidneys—not just by ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among hospitalized adults with type 2 diabetes from 2015 ...

Participants who consumed at least one serving of ultra-processed meat a day were 17% more at risk of developing cognitive ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ. The authors ...

In a recent study published in the European Heart Journal, researchers assessed the impact of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors on type 2 diabetes and heart failure (HF) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors ...

A scoring system that predicts risk for new heart failure (HF) over 5 years that is based solely on a few familiar, readily available biomarkers could potentially help steer patients with diabetes or ...